Medacta Group SA/Fr. MOVE

1D1W1MYTD1Y5YMAX

About Medacta Group SA

Medacta Group SA is a Swiss-based company specializing in the design, production, and distribution of orthopedic medical devices. The company's core business focuses on hip and knee replacement products, as well as spine surgery and sports medicine solutions. Founded in 1999, Medacta is headquartered in Castel San Pietro, Switzerland. The company distinguishes itself through its commitment to medical education, providing training and resources to healthcare professionals to enhance surgical outcomes. Medacta also emphasizes innovation in minimally invasive surgical techniques and personalized solutions to improve patient care and recovery times.
Ticker
Fr. MOVE
Sector
Health
Primary listing
XSWX
Employees
2,273
Headquarters
Castel San Pietro, Switzerland
Website
www.medacta.com

Medacta Group SA Metrics

BasicAdvanced
CHF 2.2B
30.03
CHF 3.66
0.97
CHF 1.10
0.50%

Bulls say / Bears say

H1 2026 revenue rose 9.7% in constant currency to €368m despite a strong comparison base, with double-digit growth in EMEA and Asia-Pacific. Management retained its 10–14% 2026 growth target and 12–15% 2024–27 revenue CAGR. (EQS News)
Medacta is extending its digital surgical platform beyond existing products. NextAR Hip has begun limited-market release after initial US and Australian cases, while NextAR Shoulder has expanded into complex deformity and revision procedures in the US, creating more opportunities to sell implants alongside enabling technology. (Becker's Spine Review, Medacta Corporate)
The business is still producing a sizeable operating profit while investing for expansion. H1 adjusted EBITDA was €97m, equal to a 27.8% constant-currency margin, and management still expects roughly 50 basis points of margin improvement for 2026. (EQS News, StockAnalysis)
Profitability is under pressure even as sales grow. Reported gross margin fell to 65.2% from 68.3%, hit by foreign exchange, price erosion, product and regional mix, higher depreciation and fuel-related transport costs. (EQS News, TipRanks)
North America is a near-term weak spot. H1 constant-currency growth was 6.6%, while a US Spine sales-channel transition and softer demand from existing joint customers mean the company needs about 14.3% second-half growth to reach the midpoint of its full-year guidance. (Tradevae, EQS News)
Cash generation is being stretched by the expansion programme. H1 free cash flow was negative €18.6m after €74m of capital expenditure, while further spending on manufacturing capacity and market launches could delay the improvement in earnings and cash returns that the valuation assumes. (Simply Wall St, Orthopedics This Week)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.

Funds containing Medacta Group SA

AllEURGBPUSD
Funds
Fund name
Fund size
Fr. MOVE weighting
iShares Ageing Population€AGED
€822M0.07%
Xtrackers MSCI Europe Small Cap€DX2J
€3.2B0.05%
Xtrackers MSCI Europe Small Cap£XXSC
£2.8B0.05%
iShares MSCI World Small Cap$WSML
$9B0.01%
iShares MSCI World Small Cap€IUSN
€7.8B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.